Athena Diagnostics filed its petition for certiorari with the U.S. Supreme Court yesterday in Athena Diagnostics v. Mayo Collaborative Services. There is a strong argument for the Court to grant the petition, and patent stakeholders on all sides are sure to weigh in via amicus briefs over the next month. The petition could represent the best chance for clarifying Section 101 law in the near-term, since patent reform efforts on the topic have been seemingly stalled. Below are a few initial reactions from the patent community to Athena’s arguments.
- Perryman PTAB Study for Unified Patents Leaves Out Half of the Story
- Patents are from Mars, Trade Secrets are From Venus
- The Rise of Australia’s Small Boutique Patent and Trademark Firms
- Tech Companies Should Strongly Consider Monetizing Their Patent Portfolios During the Economic Downturn
- (Not) Copyright Infringement: Is dbrand Infringing Nintendo’s IP?
- Other Barks & Bites for Friday, August 7: USPTO Increases Fees for Patent Filings and AIA Trials, State AGs Ask HHS to March-In on Remdesivir, CAFC Denies American Axle Rehearing
- No, You Can’t March in On Remdesivir
- Google v. Oracle Perspective: Google’s Android ‘Cheat Code’ was to Copy Oracle’s Code
- Illumina v. Ariosa: En Banc Rehearing Denied, Illumina Patents Again Upheld on Rehearing
- CAFC Evenly Splits on En Banc Rehearing of American Axle’s Driveshaft Patent